622 results on '"MARTIGNONI G"'
Search Results
2. Pathology Imagebase—a reference image database for standardization of pathology
- Author
-
Egevad, Lars, Cheville, John, Evans, Andrew J, Hörnblad, Jonas, Kench, James G, Kristiansen, Glen, Leite, Katia R M, Magi‐Galluzzi, Cristina, Pan, Chin‐Chen, Samaratunga, Hemamali, Srigley, John R, True, Lawrence, Zhou, Ming, Clements, Mark, Delahunt, Brett, Argani, P., Berney, D. M., Bostwick, D. G., Brunelli, M., Chen, Y, Cheng, L., Comperat, E., Eble, J., Fine, S. W., Fleming, S., Grignon, D. J., Hansel, D., Hartmann, A., Hes, O., Humphrey, P., Iczkowski, K. A., Kunju, L., Leite, K., Lopez‐Beltran, A., McKenney, J., Martignoni, G., Moch, H., Netto, G., Oxley, J., Paner, G. P., Sesterhenn, I., Shanks, J. H., Takahashi, H., Tavora, F., Teng, X., Tickoo, S., Tsuzuki, T., van der Kwast, T., and Varma, M.
- Published
- 2017
- Full Text
- View/download PDF
3. Pathology
- Author
-
Capelli, P., Martignoni, G., Scarpa, A., Zamboni, G., Pesci, A., Baert, A. L., editor, Sartor, K., editor, Procacci, Carlo, editor, and Megibow, Alec J., editor
- Published
- 2003
- Full Text
- View/download PDF
4. B5 - Addressing the best treatment for non-clear cell renal cell carcinoma (nccRCC): a meta-analysis of randomized clinical trials comparing VEGFR-TKis versus mTORi targeted therapies
- Author
-
Ciccarese, C., Iacovelli, R., Massari, F., Brunelli, M., Bimbatti, D., Fantinel, E., De Marco, V., Porcaro, A.B., Martignoni, G., Artibani, W., and Tortora, G.
- Published
- 2017
- Full Text
- View/download PDF
5. Biochemical Modulation of Fluoropyrimidines: the 'Giscad' Studies
- Author
-
Labianca, R., Pancera, G., Barni, S., Cascinu, S., Comella, G., Foa, P., Martignoni, G., Zaniboni, A., Giaccon, G., Luporini, G., and Rustum, Youcef M., editor
- Published
- 1993
- Full Text
- View/download PDF
6. Non-Hodgkin’s Lymphomas in Patients with AIDS
- Author
-
Tirelli, U., Vaccher, E., Errante, D., Crosato, I., Rezza, G., Lazzarin, A., Foà, R., Pileri, S., Carbone, A., Ambrosini, G., Andriani, A., Barberis, M., Barbui, M., Bernasconi, C., Silvestroni, I. Bianco, Borri, A., Bottinelli, G., Broccia, G., Bullian, P. L., Cajozzo, A., Cargnel, A., Cazzaniga, P., Chiodo, F., Chisesi, T., Clerici, M., Costigliola, P., Crocchiolo, P., De Lalla, F., Della Santa, M., Dessalvi, P., Fiaccadori, F., Figoli, F., Florentino, M., Franchi, M., Garavelli, P. L., Gherlinzoni, F., Gianelli, F., Giudici, M. G., Guglielmi, C., Deliliers, G. Lambertenghi, Lanza, F., Lombardi, F., Luzi, G., Luzzati, R., Malfitano, A., Malleo, C., Mandelli, F., Marangolo, M., Maringos, A., Martignoni, G., Milo, D., Montesarchio, V., Ortona, L., Palmieri, G., Parrinello, E. A., Piersantelli, N., Pizzoccaro, G., Pristerà, C., Puppo, F., Quaglino, A., Raise, E., Riccardi, A., Ricchi, E., Rizzardini, G., Rizzi, M., Rizzo, F., Rosci, A. M., Rossi, G., Sabbatani, S., Saliva, G., Salvi, G., Saracchini, S., Scalise, G., Scanni, A., Sinicco, A., Sorio, R., Squadrini, V. A., Stellini, R., Pansa, V. Stracca, Sulis, E., Surbone, A., Terragna, A., Tognetti, A., Vaglia, A., Zagni, R., Zagonel, V., Gavosto, F., Monfardini, S., Veronesi, U., editor, and Monfardini, Silvio, editor
- Published
- 1990
- Full Text
- View/download PDF
7. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas
- Author
-
Martignoni, G, Pea, M, Gobbo, S, Brunelli, M, Bonetti, F, Segala, D, Pan, Chin-Chen, Netto, G, Doglioni, C, Hes, O, Argani, P, and Chilosi, M
- Published
- 2009
- Full Text
- View/download PDF
8. Typical signs of oncocytic papillary renal cell carcinoma in everyday clinical praxis
- Author
-
Ürge, T., Hes, O., Ferda, J., Chudáček, Z., Eret, V., Michal, M., Brunelli, M., Martignoni, G., and Hora, M.
- Published
- 2010
- Full Text
- View/download PDF
9. Fragments d’anthropologie clinique en action
- Author
-
Martignoni, G.
- Published
- 2007
- Full Text
- View/download PDF
10. Resource-constrained innovation at the BoP: evidences from a digital startup
- Author
-
Pisoni, A., Michelini, L., and Martignoni, G.
- Published
- 2020
11. Dataset for the reporting of carcinoma of renal tubular origin: recommendations from the International Collaboration on Cancer Reporting (ICCR)
- Author
-
Delahunt, B, Srigley, J R, Judge, M J, Amin, M B, Billis, A, Camparo, P, Evans, A J, Fleming, S, Griffiths, D F, Lopez-Beltran, A, Martignoni, G, Moch, H, Nacey, J N, Zhou, M, University of Zurich, and Delahunt, B
- Subjects
2734 Pathology and Forensic Medicine ,10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health ,2722 Histology - Published
- 2019
12. Estrogen receptors in 699 primary breast cancers: A comparison of immunohistochemical and biochemical methods
- Author
-
Molino, A., Micciolo, R., Turazza, M., Bonetti, F., Piubello, Q., Corgnati, A., Sperotto, L., Martignoni, G., Bonetti, A., Nortilli, R., Castelli, P., Rodella, S., Capelli, P., Manfrin, E., Pelosi, G., and Cetto, G. L.
- Published
- 1995
- Full Text
- View/download PDF
13. PROGNOSTIC VALUE OF VASCULAR AND LYMPHATIC INVASION IN PATIENTS WHO HAVE UNDERGONE RADICAL CYSTECTOMY FOR TRANSITIONAL CELL CARCINOMA OF THE BLADDER
- Author
-
Valcamonico, F., Frisinghelli, M., Padovani, M., Merlin, F., Martignoni, G., Brunelli, M., Porcaro, A., Ghimenton, C., Sava, T., and Cetto, G. L.
- Published
- 2003
14. CHRONOMODULATED DELIVERY SCHEDULE OF OXALIPLATIN, 5-FLUOROURACIL AND FOLINIC ACID (FFL4/10) AS FIRST LINE TREATMENT IN METASTATIC COLORECTAL CANCER (CC): PRELIMINARY DATA OF A PHASE II STUDY
- Author
-
Quintè, A., Pirovano, M., Masseroni, S., Romanelli, A., Martignoni, G., Scaglione, F., Fraschini, F., Tabiadon, D., and Luporini, G.
- Published
- 2003
15. OXALIPLATIN (OX) AND WEEKLY BOLUS 5-FU PLUS FOLINIC ACID (FA) AS FIRST-LINE TREATMENT FOR ADVANCED COLORECTAL CANCER (ACC). A G.I.S.C.A.D. STUDY: 2356
- Author
-
Zaniboni, Alberto, Barni, S, Aitini, E, Beretta, G, Mandalaʼ, M, Meriggi, F, Mastore, M, Cabiddu, M, and Martignoni, G
- Published
- 2002
16. Validation of the 2009 TNM Version in a Large Multi-Institutional Cohort of Patients Treated for Renal Cell Carcinoma: Are Further Improvements Needed?
- Author
-
Novara, G, Ficarra, V, Antonelli, A, Artibani, W, Bertini, R, Carini, M, Cosciani Cunico, S, Imbimbo, C, Longo, N, Martignoni, G, Martorana, G, Minervini, A, Mirone, V, Montorsi, F, Schiavina, R, Simeone, C, Serni, S, Simonato, A, Siracusano, S, Volpe, A, Carmignani, G, De Cobelli O, SATURN Project LUNA F. o. u. n. d. a. t. i. o. n., Corti, S, Castelli, M, Cimino, S, Favilla, V, Morgia, G, Billia, M, Terrone, C, Masieri, L, Oneto, F, Varca, V, Rocco, F, Costantini, E, Porena, M, Zucchi, A, Ciciliato, S, Lampropoulou, N, Fontana, D, Gontero, Paolo, Tizzani, Alessandro, Brunelli, M, Valotto, C, Zattoni, F., Novara, G, Ficarra, V, Antonelli, A, Artibani, W, Bertini, R, Carini, M, Cosciani Cunico, S, Imbimbo, Ciro, Longo, Nicola, Martignoni, G, Martorana, G, Minervini, A, Mirone, Vincenzo, Montorsi, F, Schiavina, R, Simeone, C, Serni, S, Simonato, A, Siracusano, S, Volpe, A, Carmignani, G., Novara, Giacomo, Ficarra, Vincenzo, Antonelli, Alessandro, Artibani, Walter, Bertini, Roberto, Carini, Marco, Cunico Sergio, Cosciani, Martignoni, Guido, Martorana, Giuseppe, Minervini, Andrea, Montorsi, Francesco, Schiavina, Roberto, Simeone, Claudio, Serni, Sergio, Simonato, Alchiede, Siracusano, Salvatore, Volpe, Alessandro, Carmignani, Giorgio, G., Novara, V., Ficarra, A., Antonelli, W., Artibani, R., Bertini, M., Carini, S. C., Cunico, N., Longo, G., Martignoni, G., Martorana, A., Minervini, F., Montorsi, R., Schiavina, C., Simeone, S., Serni, A., Simonato, S., Siracusano, A., Volpe, G., Carmignani, Novara G., Ficarra V., Antonelli A., Artibani W., Bertini R., Carini M., Cosciani Cunico S., Imbimbo C., Longo N., Martignoni G., Martorana G., Minervini A., Mirone V., Montorsi F., Schiavina R., Simeone C., Serni S., Simonato A., Siracusano S., Volpe A., Carmignani G., De Cobelli O., Corti S., Castelli M., Cimino S., Favilla V., Morgia G., Billia M., Terrone C., Masieri L., Oneto F., Varca V., Rocco F., Costantini E., Porena M., Zucchi A., Ciciliato S., Lampropoulou N., Fontana D., Gontero P., Tizzani A., Brunelli M., Valotto C., Zattoni F., Petralia G., Roscigno M., Strada E., NOVARA G, FICARRA V, ANTONELLI A, ARTIBANI W, BERTINI R, CARINI M, COSCIANI CUNICO S, IMBIMBO C, LONGO N, MARTIGNONI G, MARTORANA G, MINERVINI A, MIRONE V, MONTORSI F, SCHIAVINA R., SIMEONE C, SERNI S, SIMONATO A, SIRACUSANO S, VOLPE A, CARMIGNANI G, SATURN PROJECT-LUNA FOUNDATION., ERRATUM IN: EUR UROL. 2011 JAN, 59(1):182. SCHIAVINA, ROBERTO [CORRECTED TO SCHIAVINA, RICCARDO]., Imbimbo, C, Longo, N, Mirone, V, Carmignani, G, and SATURN Project LUNA, Foundation
- Subjects
Male ,Nephrology ,Oncology ,IMPACT ,medicine.medical_treatment ,Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? ,Kidney neoplasm ,Nephrectomy ,Renal cell carcinoma ,TNM ,Urology ,Cohort Studies ,renal cell carcinoma ,staging system ,PROPOSAL ,PRIMARY TUMOR CLASSIFICATION ,NEPHRECTOMY ,RECLASSIFICATION ,kidney cancer ,RADICAL NEPHRECTOMY ,Middle Aged ,Primary tumor ,Kidney Neoplasms ,REVISION ,classification ,Cohort ,CUTOFF ,Aged ,Carcinoma, Renal Cell ,Female ,Humans ,Neoplasm Staging ,Retrospective Studies ,kidney neoplasm ,Human ,medicine.medical_specialty ,TNM staging system ,STRATIFICATION ,Internal medicine ,medicine ,business.industry ,Carcinoma ,Renal Cell ,Retrospective cohort study ,medicine.disease ,Surgery ,SIZE ,Cohort Studie ,business ,Kidney cancer ,Kidney disease - Abstract
Background: A new edition of the TNM was recently released that includes modifications for the staging system of kidney cancers. Specifically, T2 cancers were subclassified into T2a and T2b ( 10 cm), tumors with renal vein involvement or perinephric fat involvement were classified as T3a cancers, and those with adrenal involvement were classified as T4 cancers. Objective: Our aim was to validate the recently released edition of the TNM staging system for primary tumor classification in kidney cancer. Design, setting, and participants: Our multicenter retrospective study consisted of 5339 patients treated in 16 academic Italian centers. Intervention: Patients underwent either radical or partial nephrectomy. Measurements: Univariable and multivariable Cox regression models addressed cancer-specific survival (CSS) after surgery. Results and limitations: In the study, 1897 patients (35.5%) were classified as pT1a, 1453 (27%) as pT1b, 437 (8%) as pT2a, 153 (3%) as pT2b, 1059 (20%) as pT3a, 117 (2%) as pT3b, 26 (0.5%) as pT3c, and 197 (4%) as pT4. At a median follow-up of 42 mo, 786 (15%) had died of disease. In univariable analysis, patients with pT2b and pT3a tumors had similar CSS, as did patients with pT3c and pT4 tumors. Moreover, both pT3a and pT3b stages included patients with heterogeneous outcomes. In multivariable analysis, the novel classification of the primary tumor was a powerful independent predictor of CSS (p for trend < 0.0001). However, the substratification of pT1 tumors did not retain an independent predictive role. The major limitations of the study are retrospective design, lack of central pathologic review, and the small number of patients included in some substages. Conclusions: The recently released seventh edition of the primary tumor staging system for kidney tumors is a powerful predictor of CSS. However, some of the substages identified by the classification have overlapping prognoses, and other substages include patients with heterogeneous outcomes. The few modifications included in this edition may have not resolved the most critical issues in the previous version. (C) 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
- Published
- 2010
17. CISPLATIN (CDDP), 5-FLUOROURACIL (5FU) BOLUS AND CONTINUOUS INFUSION AND FOLINIC ACID (FA) IN THE TREATMENT OF CANCER OF THE BILIARY SYSTEM: A PROSPECTIVE PHASE II TRIAL.
- Author
-
Meregalli, M, Beretta, G D, Mosconi, S, Frontini, L, Barni, S, Labianca, R, Martignoni, G, and Luporini, G
- Published
- 2000
18. IS THERE ANY CLINICAL PROGNOSTIC INDEX OF RESISTANCE TO 5-FLUOROURACIL (5FU) IN THE TREATMENT OF COLORECTAL CANCER? PRELIMINARY RESULTS OF A MONO-INSTITUTIONAL EXPERIENCE.
- Author
-
Martignoni, G, Meregalli, M, Quintè, A, Pirovano, M, Tedeschi, L, Masseroni, S, Valsecchi, R, Paganoni, A M, and Luporini, G
- Published
- 2000
19. Expression of MHC class I and class II antigens in pancreatic adenocarcinomas
- Author
-
Scupoli, M. T., Sartoris, S., Tosi, G., Ennas, M. G., Nicolis, M., Cestari, T., Zamboni, G., Martignoni, G., Lemoine, N. R., Scarpa, A., and Accolla, R. S.
- Published
- 1996
20. Clear Cell (“Sugar”) Tumor Of The Lung Is A Lesion Strictly Related To Angiomyolipoma—: The concept of a family of lesions characterized by the presence of the perivascular epithelioid cells (PEC)
- Author
-
Bonetti, F., Pea, M., Martignoni, G., Doglioni, C., Zamboni, G., Capelli, P., Rimondi, P., and Andrion, A.
- Published
- 1994
- Full Text
- View/download PDF
21. A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma
- Author
-
Smith, SC, Sirohi, D, Ohe, C, McHugh, JB, Hornick, JL, Kalariya, J, Karia, S, Snape, K, Hodgson, SV, Cani, AK, Hovelson, D, Luthringer, DJ, Martignoni, G, Chen, Y-B, Tomlins, SA, Mehra, R, and Amin, MB
- Subjects
urologic and male genital diseases ,female genital diseases and pregnancy complications - Abstract
AIMS: Fumarate hydratase (FH)-deficient renal cell carcinoma (RCC) is a high-grade, aggressive tubulopapillary carcinoma, arising predominantly in the setting of the hereditary leiomyomatosis-RCC syndrome of familial uterocutaneous leiomyomatosis and deficiency of FH. In contrast, succinate dehydrogenase (SDH)-deficient RCC is a lower-grade oncocytic carcinoma with cytoplasmic flocculence/vacuolation and inclusions, arising mostly in individuals harbouring germline mutations of subunit B of the SDH complex (SDHB). Herein we aim to report the clinicopathologic features of a novel form of FH-deficient RCC showing a low grade oncocytic morphology, reminiscent of SDH-deficient RCC. METHODS AND RESULTS: These distinctive, low-grade oncocytic neoplasms, with solid, nested and focally tubular architecture (2-90 mm), arose in four males (aged 11-41 years). Uniform cytology of polygonal cells, with flocculent, vacuolated eosinophilic cytoplasm with scattered inclusions, fine chromatin, and inconspicuous nucleoli, was apparent. Despite these features suggestive of SDH-deficient RCC, each tumour was confirmed as an FH-deficient carcinoma with retained SDHB expression. One case showed a synchronous, anatomically separate, typical high-grade FH-deficient RCC; one other showed such a tumour at nephrectomy 4 years later. No progression has been noted at 3 and 7 years in the cases with only the SDH-like lesions; the two cases with separate, typical FH-deficient RCCs progressed. CONCLUSIONS: In summary, we characterize a novel oncocytic type of FH-deficient RCC with a striking resemblance to SDH-deficient RCC, posing a diagnostic challenge and raising concerns about sampling and multifocality for syndrome-associated cases under surveillance protocols.
- Published
- 2017
22. L’università dell’Utopia. La Statale di Milano negli anni Settanta
- Author
-
Coen Porosini, A., Dionigi, R., Generali, D., Botta, M., Capanna, M., Bellini, R., Baldini, F., Carrozzini, G., Veneziano, R., Martignoni, G. M., Giannitrapani, P., Vedibene, M., Brebbia, G., Meazza, C., Petitot, J., Sini, C., Bianca, M., Broggini, G., Cambria, F., Rodríguez, R. A., Fabbrichesi, R., Handjaras, L., Maiorca, B., Biuso, A. G., Agazzi, E., Heinzmann, G., Coliva, A., Gonzalez, W. J., Arrojo, M. J., Coniglione, F., Negro, M., Chiffi, D., Sabatini, N., Schiavio, F., Taramelli, R., Lenk, H., Maring, M., Cambi, F., Buzzoni, M., Galuzzi, M., Quaranta, M., Renzi, E., Ferri, M. B., Paladini, A., Giannì, I., Scaramuzza, G., Dino, O., DALLA VIGNA, PIERRE ALESSANDRO, Paganini, G., Galli, S. B., Pozzi, P., Kemp, P., Lazzari, M., Marinotti, A., Colonnello, P., Piccari, P., Quarta, A., Vinti, C., Micheli, G., Bazhanov, V. A., Panza, M., Cimino, G., Luzzini, F., Vaccari, E., Wolenski, J., Rossi, A., Bertagna, G., Bartolini, R., Tussi, T., Scolozzi, E., Hagström, E., Ponzellini, V., Patti, A., Barile, S., Veca, S., Frascanetti Brondino, Y., Visconti, K., Orecchia, A. M., Sandrini, M. G., Dobner, C., Moccia, N., Brondino, M., Velázquez, L., Brondino, L., Papi, F., Brissa, E., de Paoli, M., Riccobono, M. G., Santi, G., Pasetti, C., and Martignoni, G.
- Published
- 2015
23. The WHO ISUP classification of renal tumors: What has changed?
- Author
-
Martignoni, G., primary
- Published
- 2018
- Full Text
- View/download PDF
24. Addressing the best treatment for non-clear cell renal cell carcinoma (nccRCC): a meta-analysis of randomized clinical trials comparing VEGFR-TKis versus mTORi targeted therapies
- Author
-
Ciccarese, C., primary, Iacovelli, R., additional, Massari, F., additional, Brunelli, M., additional, Bimbatti, D., additional, Fantinel, E., additional, De Marco, V., additional, Porcaro, A.B., additional, Martignoni, G., additional, Artibani, W., additional, and Tortora, G., additional
- Published
- 2017
- Full Text
- View/download PDF
25. Prognostic factors in a large multi-institutional series of papillary renal cell carcinoma
- Author
-
Zucchi, A, Novara, G, Costantini, E, Antonelli, A, Carini, M, Carmignani, G, Cosciani Cunico, S, Fontana, Dario, Longo, N, Martignoni, G, Minervini, A, Mirone, V, Porena, M, Roscigno, M, Schiavina, R, Simeone, C, Simonato, A, Siracusano, S, Terrone, Carlo, Ficarra, V., ZUCCHI A, NOVARA G, COSTANTINI E, ANTONELLI A, CARINI M, CARMIGNANI G, COSCIANI CUNICO S, FONTANA D, LONGO N, MARTIGNONI G, MINERVINI A, MIRONE V, PORENA M, ROSCIGNO M, SCHIAVINA R., SIMEONE C, SIMONATO A, SIRACUSANO S, TERRONE C, FICARRA V., Zucchi, A, Novara, G, Costantini, E, Antonelli, A, Carini, M, Carmignani, G, Cosciani Cunico, S, Fontana, D, Longo, N, Martignoni, G, Minervini, A, Mirone, V, Porena, M, Roscigno, M, Schiavina, R, Simeone, C, Simonato, A, Siracusano, Salvatore, Terrone, C, Ficarra, V., Zucchi, Alessandro, Novara, Giacomo, Costantini, Elisabetta, Antonelli, Alessandro, Carini, Marco, Carmignani, Giorgio, Cosciani Cunico, Sergio, Fontana, Dario, Longo, Nicola, Martignoni, Guido, Minervini, Andrea, Mirone, Vincenzo, Porena, Massimo, Roscigno, Marco, Schiavina, Riccardo, Simeone, Claudio, Simonato, Alchiede, Terrone, Carlo, Ficarra, Vincenzo, A., Zucchi, G., Novara, E., Costantini, A., Antonelli, M., Carini, G., Carmignani, S. C., Cunico, D., Fontana, G., Martignoni, A., Minervini, M., Porena, M., Roscigno, R., Schiavina, C., Simeone, A., Simonato, S., Siracusano, C., Terrone, and V., Ficarra
- Subjects
Male ,renal cell carcinoma ,Time Factors ,Papillary renal cell carcinoma ,Prognostic factors ,Prognosi ,FEATURES ,kidney cancer ,papillary ,papillary adenocarcinoma ,prognostic factors ,papillary renal cell carcinoma ,Nephrectomy ,CLASSIFICATION ,Follow-Up Studie ,cancer-specific survival ,Risk Factors ,Retrospective Studie ,Cause of Death ,Prevalence ,Humans ,recurrence-free survival ,prognostic factor ,Carcinoma, Renal Cell ,TYPE-1 ,Proportional Hazards Models ,Retrospective Studies ,Neoplasm Staging ,Academic Medical Centers ,Risk Factor ,Kidney Neoplasm ,Middle Aged ,Prognosis ,TUMORS ,Kidney Neoplasms ,HISTOLOGIC SUBTYPES ,Prognostic factors in a large multi-institutional series of papillary renal cell carcinoma ,Survival Rate ,Academic Medical Center ,Italy ,SURVIVAL ,Proportional Hazards Model ,Female ,Follow-Up Studies ,Human - Abstract
OBJECTIVES To investigate cancer-related outcomes and prognostic factors of papillary renal cell carcinoma (pRCC) in a large multicentre data set. Oncological outcome and prognostic factors of pRCC have been limitedly evaluated in comparison with the most common RCC subtype, clear cell RCC. PATIENTS AND METHODS From a multicentre retrospective database, including 5463 patients who were surgically treated for RCC at 16 Italian academic centres between 1995 and 2007, 577 patients with pRCC were identified. Univariable and multivariable Cox regression models were performed to identify prognostic factors predictive of recurrence-free survival (RFS) and cancer-specific survival (CSS) after surgery. RESULTS At a median (interquartile range) follow-up of 39.2 (21.7-72) months, 81 (14%) patients had experienced disease progression and 63 (11%) patients had died from disease; the 5-year RFS estimate was 85.5%. In multivariable analysis, pathological N stage (pooled P < 0.001), M stage (hazard ratio, 2.9; P = 0.007) and Fuhrman nuclear grade (pooled P = 0.039) were all independent predictors of RFS; the 5-year CSS estimate was 87.9%. In Cox multivariable analysis, an independent predictive role was reconfirmed for mode of presentation (pooled P = 0.038), pathological N stage (pooled P < 0.001), M stage (hazard ratio, 2.4; P = 0.049) and Fuhrman nuclear grade (pooled P = 0.037). CONCLUSIONS Patients with pRCC have a low risk of tumour recurrence and cancer-related death after surgery. Fuhrman nuclear grade was found to be a stronger predictor of both RFS and CSS, whereas only a non-statistically significant trend was found for the 2009 pathological T stage.
- Published
- 2012
26. A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer
- Author
-
Cascinu, S., Silva, R.R., Labianca, R., Barni, S., Mattioli, R., Martignoni, G., Frontini, L., Gasparini, G., Catalano, V., Baldelli, A.M., Giuliodori, L., Agostinelli, R., and Catalano, G.
- Published
- 1999
- Full Text
- View/download PDF
27. Erratum: Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: Are further improvements needed? (European Urology (2010) 58 (588-95))
- Author
-
Novara, G, Ficarra, V, Antonelli, A, Artibani, W, Bertini, R, Carini, M, Cosciani Cunico, S, Imbimbo, C, Longo, N, Martignoni, G, Martorana, G, Minervini, A, Mirone, V, Montorsi, F, Schiavina, R, Simeone, C, Serni, S, Simonato, A, Siracusano, S, Volpe, A, Carmignani, G, SATURN Project-LUNA, Foundation., Novara G., Ficarra V., Antonelli A., Artibani W., Bertini R., Carini M., Cunico S.C., Imbimbo C., Longo N., Martignoni G., Martorana G., Minervini A., Mirone V., Montorsi F., Schiavina R., Simeone C., Serni S., Simonato A., Siracusano S., Volpe A., Carmignani G., NOVARA G, FICARRA V, ANTONELLI A, ARTIBANI W, BERTINI R, CARINI M, COSCIANI CUNICO S, IMBIMBO C, LONGO N, MARTIGNONI G, MARTORANA G, MINERVINI A, MIRONE V, MONTORSI F, SCHIAVINA R., SIMEONE C, SERNI S, SIMONATO A, SIRACUSANO S, VOLPE A, CARMIGNANI G, SATURN PROJECT-LUNA FOUNDATION., Novara, G, Ficarra, V, Antonelli, A, Artibani, W, Bertini, R, Carini, M, Cosciani Cunico, S, Imbimbo, C, Longo, N, Martignoni, G, Martorana, G, Minervini, A, Mirone, V, Montorsi, F, Schiavina, R, Simeone, C, Serni, S, Simonato, A, Siracusano, Salvatore, Volpe, A, Carmignani, G, and SATURN Project LUNA, Foundation
- Subjects
Oncology ,medicine.medical_specialty ,Corrigendum to ‘‘Validation of the 2009 TNM Version in a Large ,business.industry ,Urology ,Renal Cell Carcinoma ,medicine.disease ,TNM ,Renal cell carcinoma ,Internal medicine ,Cohort ,medicine ,business ,erratum error priority journal - Abstract
A new edition of the TNM was recently released that includes modifications for the staging system of kidney cancers. Specifically, T2 cancers were subclassified into T2a and T2b (< or =10 cm vs >10 cm), tumors with renal vein involvement or perinephric fat involvement were classified as T3a cancers, and those with adrenal involvement were classified as T4 cancers. OBJECTIVE: Our aim was to validate the recently released edition of the TNM staging system for primary tumor classification in kidney cancer. DESIGN, SETTING, AND PARTICIPANTS: Our multicenter retrospective study consisted of 5339 patients treated in 16 academic Italian centers. INTERVENTION: Patients underwent either radical or partial nephrectomy. MEASUREMENTS: Univariable and multivariable Cox regression models addressed cancer-specific survival (CSS) after surgery. RESULTS AND LIMITATIONS: In the study, 1897 patients (35.5%) were classified as pT1a, 1453 (27%) as pT1b, 437 (8%) as pT2a, 153 (3%) as pT2b, 1059 (20%) as pT3a, 117 (2%) as pT3b, 26 (0.5%) as pT3c, and 197 (4%) as pT4. At a median follow-up of 42 mo, 786 (15%) had died of disease. In univariable analysis, patients with pT2b and pT3a tumors had similar CSS, as did patients with pT3c and pT4 tumors. Moreover, both pT3a and pT3b stages included patients with heterogeneous outcomes. In multivariable analysis, the novel classification of the primary tumor was a powerful independent predictor of CSS (p for trend
- Published
- 2011
28. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series
- Author
-
Volpe, A., Novara, G., Antonelli, A., Bertini, R., Billia, M., Carmignani, G., Cosciani Cunico, S., Longo, N., Martignoni, G., Minervini, A., Mirone, V., Simonato, A., Terrone, C., Zattoni, F., Ficarra, V., De Cobelli, O., Martorana, G., Schiavina, R., Corti, S., Simeone, C., Castelli, M., Cimino, Sebastiano, Favilla, V., Morgia, Giuseppe Maria, Imbimbo, C., Carini, M., Masieri, L., Serni, S., Oneto, F., Varca, V., Rocco, F., Valotto, C., Costantini, E., Porena, M., Zucchi, A., Ciciliato, S., Lampropoulou, N., Siracusano, S., Fontana, D., Gontero, P., Tizzani, A., Artibani, W., Brunelli, M., Montorsi, F., Petralia, G., Roscigno, M., Strada, E., Alessandro Volpe, Giacomo Novara, Alessandro Antonelli, Roberto Bertini, Michele Billia, Giorgio Carmignani, Sergio Cosciani Cunico, Nicola Longo, Guido Martignoni, Andrea Minervini, Vincenzo Mirone, Alchiede Simonato, Carlo Terrone, Filiberto Zattoni, Vincenzo Ficarra, members of the Surveillance and Treatment Update on Renal Neoplasms (SATURN) Project – Leading Urological No-Profit Foundation for Advanced Research (LUNA) Foundation [.., Riccardo Schiavina, ], Volpe, A., Novara, G., Antonelli, A., Bertini, R., Billia, M., Carmignani, G., Cosciani Cunico, S., Longo, N., Martignoni, G., Minervini, A., Mirone, V., Simonato, A., Terrone, C., Zattoni, F., Ficarra, V., De Cobelli, O., Martorana, G., Schiavina, R., Corti, S., Simeone, C., Castelli, M., Cimino, S., Favilla, V., Morgia, G., Imbimbo, C., Carini, M., Masieri, L., Serni, S., Oneto, F., Varca, V., Rocco, F., Valotto, C., Costantini, E., Porena, M., Zucchi, A., Ciciliato, Stefano, Lampropoulou, N., Siracusano, Salvatore, Fontana, D., Gontero, P., Tizzani, A., Artibani, W., Brunelli, M., Montorsi, F., Petralia, G., Roscigno, M., Strada, E., Volpe, Alessandro, Novara, Giacomo, Antonelli, Alessandro, Bertini, Roberto, Billia, Michele, Carmignani, Giorgio, Cunico, Sergio Cosciani, Longo, Nicola, Martignoni, Guido, Minervini, Andrea, Mirone, Vincenzo, Simonato, Alchiede, Terrone, Carlo, Zattoni, Filiberto, Ficarra, Vincenzo, Volpe, A, Novara, G, Antonelli, A, Bertini, R, Billia, M, Carmignani, G, Cunico, Sc, Martignoni, G, Minervini, A, Simonato, A, Terrone, C, Zattoni, F, Imbimbo, Ciro, Ciciliato, S., and Siracusano, S.
- Subjects
Male ,renal cell carcinoma ,chromophobe RCC ,prognostic factors ,Carcinoma ,Nephrectomy ,Prognosis ,Renal cell ,Kaplan-Meier Estimate ,Chromophobe renal cell carcinoma ,Chromophobe ,Humans ,Carcinoma, Renal Cell ,carcinoma ,renal cell ,chromophobe ,prognosis ,nephrectomy ,Kidney Neoplasm ,Middle Aged ,Kidney Neoplasms ,oncological outcames ,oncological outcomes and prognostic factors ,Female ,prognosi ,Human - Abstract
Study Type - Outcomes (cohort) Level of Evidence 2b What's known on the subject? and What does the study add? About 80% of RCCs have clear cell histology, and consistent data are available about the clinical and histological characteristics of this histological subtype. Conversely, less attention has been dedicated to the study of non-clear cell renal tumours Specifically, published data show that chromophobe RCC (ChRCC) have often favourable pathological stages and better nuclear grades as well as a lower risk of metastasizing compared with clear cell RCC (ccRCC). Patients with ChRCC were shown to have significantly higher cancer-specific survival (CSS) probabilities compared with ccRCC. However, an independent prognostic role of RCC histotype was not confirmed in some large multicenter series and only a few studies have focused on the oncological outcomes of ChRCC. The present study is one of the few to evaluate cancer-related outcomes of ChRCC and represents to our knowledge the largest series of ChRCCs. Consequently, the present findings may assist in elucidating the natural history of surgically treated ChRCC. The present study confirms that ChRCCs have good prognosis and a low tendency to progress and metastasize. Only 1.3% of patients presented with distant metastases at diagnosis, and the 5- and 10-year CSS were 93% and 88.9%, respectively. However, although ChRCCs are generally characterised by an excellent prognosis, we observed that patients with locally advanced or metastatic cancers as well as those with sarcomatoid differentiation have a poor outcome. The study also investigated prognostic factors for recurrence-free survival (RFS) and CSS for this RCC histotype. The definition of outcome predictors can be useful for patient counselling, planning of follow-up strategies, and patient selection for clinical trials. In the present study, gender, clinical T stage, pathological T stage, and presence of sarcomatoid differentiation were significantly associated with RFS and CSS at multivariable analysis. We also identified N/M stage as an independent predictor of CSS. Notably, as Fuhrman grade was not an independent predictor of cancer-related outcomes, the present study confirms that this histological variable is not a reliable prognostic factor for ChRCC. OBJECTIVES: To investigate cancer-related outcomes of chromophobe renal cell carcinoma (ChRCC) in a large multicentre dataset. To determine prognostic factors for recurrence-free survival (RFS) and cancer-specific survival (CSS) for this RCC histological type. PATIENTS AND METHODS: In all, 291 patients with ChRCC were identified from a multi-institutional retrospective database including 5463 patients who were surgically treated for RCC at 16 Italian academic centres between 1995 and 2007. Univariable and multivariable Cox regression models were used to identify prognostic factors predictive of RFS and CSS after surgery for ChRCC. RESULTS: At a median follow-up of 44 months, 25 patients (8.6%) had disease recurrence and 18 patients (6.2%) died from disease. The 5-year RFS and CSS rates were 89.3% and 93%, respectively. Gender (P= 0.014), clinical T stage (P= 0.017), pathological T stage (P= 0.003), and sarcomatoid differentiation (P= 0.032) were independent predictors of RFS at multivariable analysis. For CSS, there was an independent prognostic role for gender (P= 0.032) and T stage (P= 0.019) among the clinical variables and for T stage (P= 0.016), N/M stage (P= 0.023), and sarcomatoid differentiation (P= 0.015) among the pathological variables. CONCLUSIONS: Patients with ChRCC have a low risk of tumour progression, metastasis, and cancer-specific death. Patient gender, clinical and pathological tumour stage, and sarcomatoid differentiation are significant predictors of RFS and CSS for ChRCC.
- Published
- 2011
29. Papillary renal cell carcinoma
- Author
-
Delahunt, B, Algabe, F, Cheville, J, Amin, M B, Argani, P, Martignoni, G, Moch, H, Srigley, J R, Tan, P H, Tickoo, S K, University of Zurich, Moch, H, Humphrey, P A, Ulbright, T M, and Reuter, V E
- Subjects
10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health - Published
- 2016
30. Renal cell tumours
- Author
-
Moch, H, Amin, M B, Argani, P, Cheville, J, Delahunt, B, Martignoni, G, Medeiros, L J, Srigley, J R, Tan, P H, Tickoo, S K, University of Zurich, Moch, H, Humphrey, P A, Ulbright, T M, and Reuter, V E
- Subjects
2734 Pathology and Forensic Medicine ,1307 Cell Biology ,10049 Institute of Pathology and Molecular Pathology ,1312 Molecular Biology ,610 Medicine & health - Published
- 2016
31. Papillary adenoma
- Author
-
Eble, J N, Moch, H, Amin, M B, Argani, P, Cheville, J, Delahunt, B, Martignoni, G, Srigley, J R, Tan, P H, Tickoo, S K, University of Zurich, Moch, H, Humphrey, P A, Ulbright, T M, and Reuter, V E
- Subjects
10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health - Published
- 2016
32. Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification
- Author
-
Brunelli, M., Nottegar, A., Bogina, G., Caliò, A., Cima, L., Eccher, A., Vicentini, C., Marcolini, L., Aldo Scarpa, Pedron, S., Brunello, E., Knuutila, S., Sapino, A., Marchiò, C., Bria, E., Molino, A., Carbognin, L., Tortora, G., Jasani, B., Miller, K., Merdol, I., Zanatta, L., Laurino, L., Wirtanen, T., Zamboni, G., Marconi, M., Chilosi, M., Manfrin, E., Martignoni, G., and Bonetti, F.
- Subjects
false positive ,double probes ,Breast carcinoma ,aCGH method ,monosomy ,Original Article ,HER 2 amplification ,chromosome 17 ,FISH analysis ,ratio (HER2/CEP 17) ,single signals - Abstract
Monosomy of chromosome 17 may affect the assessment of HER2 amplification. Notably, the prevalence ranges from 1% up to 49% due to lack of consensus in recognition. We sought to investigate the impact of monosomy of chromosome 17 to interpretation of HER2 gene status. 201 breast carcinoma were reviewed for HER2 gene amplification and chromosome 17 status. FISH analysis was performed by using double probes (LSI/CEP). Absolute gene copy number was also scored per each probe. HER2 FISH test was repeated on serial tissue sections, ranging in thickness from 3 to 20 µm. Ratio was scored and subsequently corrected by monosomy after gold control test using the aCGH method to overcome false interpretation due to artefactual nuclear truncation. HER2 immunotests was performed on all cases. 26/201 cases were amplified (13%). Single signals per CEP17 were revealed in 7/201 (3.5%) cases. Five out of 7 cases appeared monosomic with aCGH (overall, 5/201, 2.5%) and evidenced single signals in >60% of nuclei after second-look on FISH when matching both techniques. Among 5, one case showed amplification with a pattern 7/1 (HER2/CEP17>2) of copies (3+ at immunotest); three cases revealed single signals per both probes (LSI/CEP=1) and one case revealed a 3:1 ratio; all last 4 cases showed 0/1+ immunoscore. We concluded that: 1) monosomy of chromosome 17 may be observed in 2.5% of breast carcinoma; 2) monosomy of chromosome 17 due to biological reasons rather than nuclear truncation was observed when using the cut-off of 60% of nuclei harboring single signals; 3) the skewing of the ratio due to single centromeric 17 probe may lead to false positive evaluation; 4) breast carcinomas showing a 3:1 ratio (HER2/CEP17) usually show negative 0/1+ immunoscore and
- Published
- 2015
33. Nomogram Predictive of Cancer Specific Survival in Patients Undergoing Partial or Total Amputation for Squamous Cell Carcinoma of the Penis
- Author
-
Kattan, Mw, Ficarra, Vincenzo, Artibani, W, Cunico, Sc, Fandella, A, Martignoni, G, Novara, Giacomo, Galetti, Tp, Zattoni, Filiberto, and GUONE PENILE CANCER PROJECT MEMBERS
- Subjects
Male ,nomogram ,prognostic factors ,penile cancer ,medicine.medical_specialty ,Urology ,Amputation, Surgical ,Predictive Value of Tests ,medicine ,Carcinoma ,Humans ,Penile cancer ,Penile Neoplasms ,Survival rate ,Aged ,Penectomy ,business.industry ,Middle Aged ,Nomogram ,Prognosis ,medicine.disease ,Primary tumor ,Surgery ,Survival Rate ,Nomograms ,medicine.anatomical_structure ,Epidermoid carcinoma ,Carcinoma, Squamous Cell ,Radiology ,business ,Penis - Abstract
We created the first nomograms to predict cancer specific survival probabilities of patients with squamous cell carcinoma of the penis, clustering prognostic information from the most commonly used clinical and pathological variables.We retrospectively collected clinical and pathological data from 175 patients who had undergone surgery for squamous cell carcinoma of the penis from 1980 to 2002 at 11 urological centers in northeastern Italy. A logistic regression model was used to construct the nomogram.At a median followup of 24 months, 101 patients (57.7%) were alive and disease-free while 74 (42.3%) died of penile cancer. According to multivariate analyses, 2 models predictive of cancer specific survival probability were generated. The first model was based on the pathological findings of the primary tumor after penectomy and on the clinical stage of groin lymph nodes, while the second model included the pathological data of the primary tumor and groin lymph nodes. The concordance index was 0.728 for the first model and 0.747 for the second. Calibration appeared to be good in both models.In this article we propose 2 models to predict the 5-year cancer specific survival probabilities of patients with squamous cell carcinoma of the penis. Both models showed good discriminating power and calibration in predicting patient 5-year cancer specific survival. These nomograms could improve the quality of prognostic data provided to patients and support physicians in planning treatment.
- Published
- 2006
34. Erratum: Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed?
- Author
-
NOVARA G, FICARRA V, ANTONELLI A, ARTIBANI W, BERTINI R, CARINI M, COSCIANI CUNICO S, IMBIMBO C, LONGO N, MARTIGNONI G, MINERVINI A, MIRONE V, MONTORSI F, SIMEONE C, SERNI S, SIMONATO A, SIRACUSANO S, VOLPE A, CARMIGNANI G, SATURN PROJECT LUNA FOUNDATION, MARTORANA, GIUSEPPE, SCHIAVINA, RICCARDO, NOVARA G, FICARRA V, ANTONELLI A, ARTIBANI W, BERTINI R, CARINI M, COSCIANI CUNICO S, IMBIMBO C, LONGO N, MARTIGNONI G, MARTORANA G, MINERVINI A, MIRONE V, MONTORSI F, SCHIAVINA R., SIMEONE C, SERNI S, SIMONATO A, SIRACUSANO S, VOLPE A, CARMIGNANI G, and SATURN PROJECT-LUNA FOUNDATION
- Subjects
2009 TNM ,renal cell carcinoma - Published
- 2012
35. Head-to-head Comparison of the Most Relevant Integrated Prognostic Systems Predicting Cancer-specific Survival In Clear Cell Renal Cell Carcinoma
- Author
-
Ficarra, V, Sun, M, Karakiewicz, P.I, Novara, G, Antonelli, A, Bertini, R, Carini, M, Carmignani, G, Longo, N, Martignoni, G, Martorana, G, Minervini, A, Mirone, V, Artibani, W, Zattoni, F, Simionato, A, Siracusano, S, Terrone, C, V., Ficarra, M., Sun, P. I., Karakiewicz, G., Novara, A., Antonelli, R., Bertini, M., Carini, G., Carmignani, Longo, Nicola, G., Martignoni, G., Martorana, A., Minervini, Mirone, Vincenzo, W., Artibani, F., Zattoni, A., Simionato, S., Siracusano, C., Terrone, I. K., P., N., Longo, V., Mirone, Siracusano, Salvatore, Ficarra, V., Sun, M., Karakiewicz, P. I., Novara, G., Antonelli, A., Bertini, R., Carini, M., Carmignani, G., Martignoni, G., Martorana, G., Minervini, A., Artibani, W., Zattoni, F., Simionato, A., Siracusano, S., and Terrone, C. .
- Subjects
prognostic systems predicting cancer-specific survival , clear cell renal cell carcinoma ,Prognostic Systems ,Cancer-specific Survival ,Clear Cell Renal Cell Carcinoma ,Prognostic System - Published
- 2011
36. Many facets of chromosome 3p cytogenetic findings in clear cell renal carcinoma: the need for agreement in assessment FISH analysis to avoid diagnostic errors
- Author
-
Brunelli, M., Fiorentino, M., Stefano Gobbo, Sperandio, N., Cheng, L., Cossu-Rocca, P., Segala, D., Eble, J. N., Delahunt, B., Novara, G., Ficarra, V., Martignoni, G., Brunelli M, Fiorentino M, Gobbo S, Sperandio N, Cheng L, Cossu-Rocca P, Segala D, Eble JN, Delahunt B, Novara G, Ficarra V, and Martignoni G
- Subjects
Cell Nucleus ,Chromosome Aberrations ,renal cell carcinoma ,prognostic factors ,Socio-culturale ,Kidney ,Kidney Neoplasms ,Chromosome 3 ,Polyploidy ,616 - Patología. Medicina clínica. Oncología ,Chromosome 3p ,Clear cell renal carcinoma ,Fluorescence in situ hybridization (FISH) ,Interphase ,Animals ,Humans ,Chromosomes, Human, Pair 3 ,chromosome 3p renal cell cancer ,In Situ Hybridization, Fluorescence ,Adenocarcinoma, Clear Cell - Abstract
Abnormalities of the locus chromosome 3p and the entire chromosome 3 are involved in the cancerogenesis of clear cell renal carcinoma and may be detected by interphase fluorescence in situ hybridization (interphase FISH). We observed a variable detection rate of chromosome 3p/3 abnormalities in different series of clear cell renal carcinoma. Therefore, we focused on problematic issues when performing analysis on routinely available formalin-fixed and paraffin embedded tissue. A group of studies encountered a single approach to chromosome 3p detection, by using probe/s to map different codes of the short arm 3p without a control of the entire chromosome 3. Deletion of chromosome 3p and monosomy of chromosome 3 ranged from 38% to 100% in clear cell renal carcinoma. Cut-off values for the threshold were chosen randomly or obtained by calculation of the mean value plus 1 or 2 or 3 standard deviations. Loss of chromosome 3p was assessed either as the percentage of single signals on the total number of nuclei, or applying a double approach with corrections of control chromosome 3. Moreover, cut off values were sometimes arbitrarily corrected with the findings from normal adjacent renal parenchyma. A consensus of experts in the field is needed in order to define the best methodological approach and the appropriate threshold in assessment 3p deletion when interphase FISH is performed in clear cell renal carcinoma. This harbours relevant diagnostic and therapeutic implications, at light also of targeted therapies recently available to clear cell renal carcinoma.
- Published
- 2011
37. Differential role of CD133 and CXCR4 in renal cellcarcinoma
- Author
-
D'Alterio C, Cindolo L, Portella L, Polimeno M, Consales C, Riccio A, Cioffi M, Franco R, Chiodini P, Cartenì G, Mirone V, Longo N, Marra L, Perdonà S, Claudio L, Falsaperla M, Puglisi M, Martignoni G, Ficarra V, Castello G, Scala S., MASCOLO, MASSIMO, STAIBANO, STEFANIA, D'Alterio, C, Cindolo, L, Portella, L, Polimeno, M, Consales, C, Riccio, A, Cioffi, M, Franco, R, Chiodini, P, Cartenì, G, Mirone, V, Longo, N, Marra, L, Perdonà, S, Claudio, L, Mascolo, Massimo, Staibano, Stefania, Falsaperla, M, Puglisi, M, Martignoni, G, Ficarra, V, Castello, G, and Scala, S.
- Abstract
The chemokine receptor CXCR4 and CD133, putative stem cell markers, were previously described in renal cancer (RCC). To evaluate the biological and prognostic role of CD133 and CXCR4 in RCC the expression was evaluated through qPCR and immunoblotting in human renal cancer cell lines (786-O, A498, ACHN, CAKI-1, SN12C, TK10, UO31) and patients biopsies. Renal cancer cells and surgical biopsies expressed functional CXCR4 while CD133 was not detectable. CXCR4 and CD133 expression was then evaluated in 240 renal cancer patients through immunohistochemistry. CXCR4 and CD133 were low in 19.1% and 59.6%; intermediate in 20% and 17.9%; high in 60.8% and 22.5% of the cases, respectively. CXCR4 was overexpressed in tumours (p= 0.02), while CD133 was over expressed in healthy tissues (p= 0.04). Disease free survival Kaplan Meier plots suggest that prognosis is unfavourable for patients whose primary tumours express CXCR4 (p= 0.0199) but nor CD133 (p= 0.151) neither the concomitant CXCR4-CD133 (p=0.848) high expression affected prognosis. Analysis of prognostic factors suggests that age, clinical presentation, AJCC stage and CXCR4 had a significant prognostic value at the univariate analysis. The CXCR4 predictive ability was confirmed at the multivariate analysis while no prognostic role was identified for CD133.Thus concomitant CD133 and CXCR4 evaluation is not worth in RCC patient while the CXCR4 prognostic role encourage CXCR4 antagonists as promising therapeutic option.
- Published
- 2010
38. Adenocarcinoma of the paraurethral glands: a case report
- Author
-
Francesco Massari, Ciccarese, C., Modena, A., Maines, F., Segala, D., Luchini, C., Marcolini, L., Cavicchioli, F., Cavalleri, S., Bria, E., Brunelli, M., Martignoni, G., Artibani, W., and Tortora, G.
- Subjects
urinary tract ,Urethral Neoplasms ,Lung Neoplasms ,adenocarcinoma ,Paraurethral glands ,Review ,Adenocarcinoma ,Middle Aged ,Immunohistochemistry ,Exocrine Glands ,5 - Ciencias puras y naturales::57 - Biología::576 - Biología celular y subcelular. Citología [CDU] ,Chemotherapy, Adjuvant ,Lymphatic Metastasis ,Micropapillary ,Humans ,Lymph Node Excision ,paraurethral glands ,Female ,Neoplasm Recurrence, Local ,Ultrasonography - Abstract
Adenocarcinoma of the paraurethral glands represents a very rare neoplasm of the urinary tract. Due to the rarity of this disease, there is no standard therapeutic approach. We report a case of adenocarcinoma of the paraurethral glands in a 56-year-old woman, presenting with abnormal serous vaginal discharges. The radiologic examination revealed a 5-cm mass around the urethra, which underwent surgical resection. After surgical resection, the histology revealed a moderately differentiated adenocarcinoma, probably arising from the paraurethral glands. One month later, a pelvic recurrent mass was radiologically diagnosed; consequently, an anterior pelvic exenteration with lymph node dissection was performed. Histological examination revealed a moderately differentiated adenocarcinoma, with glandular and micropapillary architecture, with multiple lymph node metastases. The absence of modifications such as urethritis cystic glandularis on the urethral mucosa, as well as the lack of a lesion in situ, associated with the immunohistochemical expression of PAX8 and negativity for GATA3 and S100p, suggested that the adenocarcinoma originated from the paraurethral glands rather than from the urethral mucosa. Post-surgery CT scans revealed no evidence of metastatic disease. The patient received 6 courses of adjuvant chemotherapy with carboplatin and paclitaxel. One year after the pelvic exenteration, because of inguinal lymph node progression, an inguinal lymphadenectomy was performed. Four months later, a TC-PET revealed a multidistrectual lymph node and a lung micronodule disease progression. Invasive micropapillary carcinomas have been characterized as a rare distinctive variant of carcinomas in several anatomic sites and are distinguished by a marked tendency to lymphovascular invasion, justifying the association with high-stage disease and poor prognosis. In the present case, both the poor prognosis connected with micropapillary structure and the lymph node involvement, encouraged adjuvant cisplatinumbased chemotherapy.
- Published
- 2014
39. Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors
- Author
-
Fiorini, C., Francesco Massari, Pedron, S., Sanavio, S., Ciccarese, C., Porcaro, A. B., Artibani, W., Bertoldo, F., Zampini, C., Sava, T., Ficial, M., Caliò, A., Chilosi, M., D Amuri, A., Sanguedolce, F., Tortora, G., Scarpa, A., Delahunt, B., Porta, C., Martignoni, G., and Brunelli, M.
- Subjects
immunofluorescence analysis ,p-mTOR ,immunohistochemical ,mTOR ,Original Article ,Western blot ,Western blot, clear cell renal cell carcinoma, immunofluorescence analysis, immunohistochemical, mTOR, methods, p-mTOR, p-p70S6k ,clear cell renal cell carcinoma ,methods ,p-p70S6k - Abstract
Since target therapy with mTOR inhibitors plays an important role in the current management of clear cell renal cell carcinoma (RCC), there is an increasing demand for predictive biomarkers, which may help to select patients that are most likely to benefit from personalized treatment. When dealing with formalin-fixed paraffin-embedded (FFPE) cancer tissue specimens, several techniques may be used to identify potential molecular markers, yielding different outcome in terms of accuracy. We sought to investigate and compare the capability of three main techniques to detect molecules performing an active function in mTOR pathway in RCC. Immunohistochemistry (IHC), Western blot (WB) and immunofluorescence (IF) analyses were performed on FFPE RCC tissue specimens from 16 patients by using the following mTOR pathway-related: mTOR (Ser235/236), phospho-mTOR (p-mTOR/Ser2448), phospho-p70S6k (p-p70S6k/Thr389), both monoclonal and polyclonal, phospho-S6Rb (p-S6Rb) and phospho-4EBP1 (p-4EBP1/Thr37/46). No single molecule was simultaneously revealed by all three techniques. Only p-p70S6k was detected by two methods (IHC and IF) using a monoclonal antibody. The other molecules were detected exclusively by one technique, as follows: p-mTOR and polyclonal p-p70S6K by IHC, p70S6K, p-S6Rb and p-4EBP1 by WB, and, finally, mTOR by IF. We found significant differences in detecting mTOR pathway-related active biomarkers by using three common techniques such as IHC, WB and IF on RCC samples. Such results have important implications in terms of predictive biomarker testing, and need to be related to clinical end-points such as responsiveness to targeted drugs by prospective studies.
- Published
- 2014
40. Basi scientifiche per la definizione di linee-guida in ambito clinico per il Carcinoma Renale
- Author
-
Boccardo F, Silvestrini R, Battaglia M, Bollito E, Bracarda S, Carini M, Carmignani G, Conti G, Corvò R, Ficarra V, Gatta G, Montorsi F, Passalacqua R, Pavlica P, Porta C, Puppo P, Salvioni R, Barozzi L. Brunelli M, Buti S, Caminiti C, Cestari A, Guazzoni G, Martignoni G, Oneto F, Ricci F, Rigatti P, Righi L, Riva M, Sangalli M, Scapaticci E, Stagni S, Tomasello L, Valentino M., MARTORANA, GIUSEPPE, FRANCESCHELLI, ALESSANDRO, SANGUEDOLCE, FRANCESCO, SCHIAVINA, RICCARDO, Boccardo F, Silvestrini R, Battaglia M, Bollito E, Bracarda S, Carini M, Carmignani G, Conti G, Corvò R, Ficarra V, Gatta G, Martorana G, Montorsi F, Passalacqua R, Pavlica P, Porta C, Puppo P, Salvioni R, Barozzi L Brunelli M, Buti S, Caminiti C, Cestari A, Franceschelli A, Guazzoni G, Martignoni G, Oneto F, Ricci F, Rigatti P, Righi L, Riva M, Sangalli M, Sanguedolce F, Scapaticci E, Schiavina R, Stagni S, Tomasello L, and Valentino M
- Subjects
Basi scientifiche per la definizione di linee-guida in ambito clinico per il Carcinoma Renale ,urologic and male genital diseases - Abstract
Basi scientifiche per la creazione delle linee guida per la diagnosi e il tratamento del tumore renale
- Published
- 2008
41. Lymphatic and Vascular Embolizations AreIndependent Predictive Variables of Inguinal LymphNode Involvement in Patients with Squamous CellCarcinoma of the Penis
- Author
-
Ficarra, V, Zattoni, F, Cunico, Sc, Galetti, Tp, Luciani, L, Fandella, A, Guazzieri, S, Maruzzi, D, Sava, T, Siracusano, Salvatore, Pilloni, S, Tasca, A, Martignoni, G, Gardiman, M, Tardanico, R, Zambolin, T, Cisternino, A, Artibani, W, Gruppo Uro Oncologico del Nord Est Penile Cancer Project, Ficarra, V, Zattoni, F, Cunico, Sc, Galetti, Tp, Luciani, L, Fandella, A, Guazzieri, S, Maruzzi, D, Sava, T, Siracusano, Salvatore, Pilloni, S, Tasca, A, Martignoni, G, Gardiman, M, Tardanico, R, Zambolin, T, Cisternino, A, Artibani, W, and Gruppo Uro Oncologico del Nord Est Penile Cancer, Project
- Subjects
squamous cell carcinoma ,penile carcinoma ,lymphatic embolization ,partial penectomy ,total penectomy ,inguinal lymph node involvement ,vascular embolization - Abstract
The objective of the current study was to identify independent clinical and pathologic variables that were predictive of lymph node involvement in patients with squamous cell carcinoma of the penis in a multicenter series with the intent to select patients who were suitable to undergo immediate inguinal lymphadenectomy. METHODS: Data were analyzed from 175 patients who underwent surgery for penile carcinoma in 11 urologic centers participating in the Gruppo Uro-Oncologico del Nord-Est (Northeast Uro-Oncological Group) Penile Cancer Data Base. Pathologically positive lymph nodes were defined as the presence of histologically confirmed lymph node metastasis in patients who underwent either immediate or delayed inguinal and/or pelvic lymphadenectomy. Patients who had clinically positive lymph nodes with cytologically positive fine-needle aspiration results and who had not undergone lymphadenectomy were censored. RESULTS: Overall, lymph-node involvement was observed in 71 of 175 patients (
- Published
- 2005
42. Autophagy and transplantation: organ injury and cancerogenesis by molecular expression of LC3B
- Author
-
Ciccarese, C., primary, Massari, F., additional, Brunelli, M., additional, Fantinel, E., additional, Bimbatti, D., additional, Eccher, A., additional, Modena, A., additional, Martignoni, G., additional, and Tortora, G., additional
- Published
- 2015
- Full Text
- View/download PDF
43. De novo renal cell neoplasia after kidney transplantation, according to the International Society of Urological Pathology (ISUP 2013) Vancouver Classification
- Author
-
Massari, F., primary, Ciccarese, C., additional, Brunelli, M., additional, Bimbatti, D., additional, Fantinel, E., additional, Eccher, A., additional, Modena, A., additional, Martignoni, G., additional, and Tortora, G., additional
- Published
- 2015
- Full Text
- View/download PDF
44. Hereditary angioneurotic oedema
- Author
-
Agostoni, A., Marasini, B., Martignoni, G. C., Cicardi, M., and Levi, L.
- Published
- 1975
- Full Text
- View/download PDF
45. Treatment of hereditary angioedema
- Author
-
Marasini, Bianca, Cicardi, M., Martignoni, G. C., and Agostoni, A.
- Published
- 1978
- Full Text
- View/download PDF
46. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters
- Author
-
Delahunt, B., Cheville, J.C., Martignoni, G., Humphrey, P.A., Magi-Galluzzi, C., McKenney, J., Egevad, L., Algaba, F., Moch, H., Grignon, D.J., Montironi, R., Srigley, J.R., and Hulsbergen-van de Kaa, C.A.
- Subjects
Translational research [ONCOL 3] ,urologic and male genital diseases - Abstract
Item does not contain fulltext The International Society of Urological Pathology 2012 Consensus Conference made recommendations regarding classification, prognostic factors, staging, and immunohistochemical and molecular assessment of adult renal tumors. Issues relating to prognostic factors were coordinated by a workgroup who identified tumor morphotype, sarcomatoid/rhabdoid differentiation, tumor necrosis, grading, and microvascular invasion as potential prognostic parameters. There was consensus that the main morphotypes of renal cell carcinoma (RCC) were of prognostic significance, that subtyping of papillary RCC (types 1 and 2) provided additional prognostic information, and that clear cell tubulopapillary RCC was associated with a more favorable outcome. For tumors showing sarcomatoid or rhabdoid differentiation, there was consensus that a minimum proportion of tumor was not required for diagnostic purposes. It was also agreed upon that the underlying subtype of carcinoma should be reported. For sarcomatoid carcinoma, it was further agreed upon that if the underlying carcinoma subtype was absent the tumor should be classified as a grade 4 unclassified carcinoma with a sarcomatoid component. Tumor necrosis was considered to have prognostic significance, with assessment based on macroscopic and microscopic examination of the tumor. It was recommended that for clear cell RCC the amount of necrosis should be quantified. There was consensus that nucleolar prominence defined grades 1 to 3 of clear cell and papillary RCCs, whereas extreme nuclear pleomorphism or sarcomatoid and/or rhabdoid differentiation defined grade 4 tumors. It was agreed upon that chromophobe RCC should not be graded. There was consensus that microvascular invasion should not be included as a staging criterion for RCC.
- Published
- 2013
47. Review of renal carcinoid tumor with focus on clinical and pathobiological aspects
- Author
-
Kuroda, N., Tanaka, A., Ohe, C., Mikami, S., Nagashima, Y., Inoue, K., Shuin, T., Taguchi, T., Tominaga, A., Alvarado-Cabrero, I., Petersson, F., Matteo BRUNELLI, Martignoni, G., Michal, M., and Hes, O.
- Subjects
Adult ,Male ,Adolescent ,Carcinoid Tumor ,Middle Aged ,Renal carcinoid tumor ,Pathology ,Chromosome 3/13 ,Kidney Neoplasms ,Young Adult ,Humans ,Female ,Aged - Abstract
Renal carcinoid tumor is a rare neoplasm. In this article, we review this neoplasm with a focus on clinical and pathobiological aspects. The majority of patients present in the fourth to seventh decades, but there is no gender predilection. Clinically, patients with renal carcinoid tumor frequently present with abdominal, back or flank pain. This tumor is occassionally associated with horseshoe kidney and/or mature cystic teratoma located in the kidney. Macroscopically, these tumors are well demarcated with a lobulated appearance and yellow or tan-brown color cut surface. Microscopically, these tumors are composed of monomorphic round to polygonal cells with granular amphophilic to eosinophilic cytoplasm. Tumor cells are arranged in trabecular, ribbon-like, gyriform, insular, glandular and solid patterns. The nuclei are round to oval and with evenly distributed nuclear chromatin, frequently with a "salt and pepper"-pattern. Immunohistochemically, tumor cells demonstrate immuno-labeling for chromogranin A and synaptophysin. Ultrastructurally, the neoplastic cells contain abundant dense core neurosecretory granules. In previous genetic studies, abnormalities of chromosomes 3 or 13 have been reported. The clinical behavior of renal carcinoid tumors is variable, but is more indolent than most renal cell carcinomas. Further investigations are warranted in order to elucidate the critical genetic abnormalities responsible for the pathogenesis of this rare entity in renal neoplastic pathology.
- Published
- 2012
48. Oncocytic papillary renal cell carcinoma: potential pitfall in small enucleation
- Author
-
Munari, E., Eccher, A., Segala, D., Iannucci, A., Stefano Gobbo, Chilosi, M., Brunelli, M., and Martignoni, G.
- Subjects
Diagnosis, Differential ,Male ,diagnostic practice ,oncocytic papillary renal cell carcinoma ,Adenoma, Oxyphilic ,Humans ,Middle Aged ,Kidney ,Carcinoma, Renal Cell ,renal oncocytoma ,Kidney Neoplasms - Abstract
We describe an emerging entity, recently recognized as a pitfall in the diagnostic practice among eosinophilic renal cell tumours.A 60-year-old male underwent enucleation of a 1.2 cm nodule. Immunohistochemistry and FISH analysis were performed.Histology revealed a neoplasm composed of large cells with eosinophilic cytoplasm, Fuhrman grade 3, arranged in papillae. At the immunohistochemical level, cells showed positivity for AMACR and CD10. Fluorescence in situ hybridization (FISH) demonstrated gains of chromosomes 7 and 17 and loss of Y. A diagnosis of oncocytic papillary renal cell carcinoma was made.The distinction between renal oncocytoma and oncocytic papillary renal cell carcinoma is of substantial importance because of their different behaviour and prognosis, since the latter has malignant potential. Although the available evidence supporting tumour enucleation as the surgical treatment for renal cortical tumoursor = 4 cm, due to aforementioned clinicopathological features such tumours need to be evaluated using appropriate immunophenotypical and cytogenetic analyses.
- Published
- 2012
49. Regulation of tight junction proteins during the epithelial-mesenchymal transition in thyroid cancer: the role of the slug transcription factor
- Author
-
Colato, C, Monzani, Fabio, Brazzarola, P, Martignoni, G, Chilosi, M, and Ferdeghini, Marco
- Published
- 2012
50. Review of renal oncocytosis (multiple oncocytic lesions) with focus on clinical and pathobiological aspects
- Author
-
Kuroda, N., Tanaka, A., Ohe, C., Mikami, S., Nagashima, Y., Sasaki, T., Inoue, K., Hes, O., Michal, M., Matteo BRUNELLI, and Martignoni, G.
- Subjects
Adult ,Aged, 80 and over ,Male ,Renal oncocytosis ,Hybrid tumor ,6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncología [CDU] ,Chromophobe renal cell carcinoma ,Oncocytoma ,Middle Aged ,urologic and male genital diseases ,Kidney Neoplasms ,Adenoma, Oxyphilic ,Humans ,Female ,Carcinoma, Renal Cell ,Aged - Abstract
Renal oncocytosis is a recently established disease entity characterized by numerous oncocytic tumors and diffuse involvement of oncocytic changes in renal parenchymal epithelia. In this article, we review this disease with a focus on its clinical and pathobiological aspects. Clinically, renal oncocytosis may occur in a sporadic form without any underlying disease or may be associated with chronic renal failure/long-term hemodialysis. However, Birt-Hogg- Dubé syndrome, characterized by skin tumors such as fibrofolliculoma or trichodiscoma, pulmonary lesions including bullae and spontaneous pneumothorax, and renal tumors should be evaluated in the differential diagnosis. The disease can develop either unilaterally or bilaterally. The involved renal parenchyma contains several to multiple brownish-colored nodules of varying size and is entirely replaced by lesions at the overt stage. Histologically, oncocytic tumors in both the dominant mass and smaller lesions encompass so-called hybrid tumor, chromophobe renal cell carcinoma (RCC), and renal oncocytoma (RO). Regarding renal parenchymal abnormalities, infiltrative growth of oncocytic cells, cortical cysts with oncocytic features, or extensive oncocytic change in non-neoplastic tubules can also be observed. Histochemical, immunohistochemical, and molecular genetic features of chromophobe RCC and RO arising in the setting of renal oncocytosis are generally identical to those in the sporadic type. However, hybrid tumors seem to be histologically distinct from chromophobe RCC and RO. In FISH analyses of some hybrid tumors, a gain of chromosomes 1, 2, 6, 10, and 17 was identified. In one tumor, no germ line mutation of folliculin gene was identified. Published data show that tumors follow a benign course. Further studies will be necesary to clarify the pathogenesis of renal oncocytosis.
- Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.